Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Centre for Eye Research Australia(CERA)

Request full access

Translational research and clinical trials for major eye diseases

Melbourne, AustraliaFounded 1996Outside Tech

About Centre for Eye Research Australia(CERA)

The Centre for Eye Research Australia (CERA) is an independent medical research institute focused on eliminating eye diseases and reducing their impact. Founded in 1996 by Professor Hugh Taylor AC, CERA was established through a collaboration between the University of Melbourne, the Royal Victorian Eye and Ear Hospital, and several associations for the blind. This structure facilitates a "bench to bedside" approach, translating basic scientific research into clinical practice. Professor Taylor, an internationally recognized clinician-scientist, served as Managing Director until 2007. The institute is currently led by Professor Keith Martin, a glaucoma specialist and gene therapy researcher who joined in 2019.

CERA operates as a non-profit, generating revenue from government grants, donations, and services, which it invests back into its research programs. The institute's core activity is conducting research and clinical trials to develop better treatments and diagnostics for major causes of blindness, such as glaucoma, macular degeneration, diabetic retinopathy, and inherited retinal diseases. Its research capabilities encompass genetics, stem cell research, artificial intelligence, and drug delivery. A key strategic priority is the development of novel therapies and providing patients with access to clinical trials for new diagnostics and treatments. CERA has also spun out commercial ventures, such as Mirugen, a biotech company that secured AUD 4.5 million in seed funding to develop treatments for retinitis pigmentosa based on cellular reprogramming technology co-developed at CERA.

Affiliated with the University of Melbourne and located at the Royal Victorian Eye and Ear Hospital, CERA works with a range of clients and partners, including patients, industry, academic institutions, and clinical services. The institute's work includes national initiatives like the first National Eye Health Survey and partnerships with Aboriginal and Torres Strait Islander health services. Through its clinical trials center, Cerulea, it aims to accelerate the delivery of new ophthalmic therapies to the community.

Source: Dealroom company data

Centre for Eye Research Australia(CERA) in the Melbourne ecosystem

Live from Dealroom

The Centre for Eye Research Australia(CERA) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Breakthrough Victoria
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇦🇺 Australia96.7%
🇮🇩 Indonesia0.7%
🇨🇳 China0.7%
🇹🇼 Taiwan0.7%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Centre for Eye Research Australia(CERA) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Centre for Eye Research Australia(CERA) on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.